On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

The clinical trial is expected to provide valuable data to further
evaluate the performance of CureVacﾒs second-generation mRNA backbone, which has the
potential to be applied broadly in future vaccines against COVID-19 variants and other
pathogens.